Cancer cells with a cell nucleus that is easily deformed are more sensitive to drugs that damage DNA. These are the findings ...

Fresenius Kabi has launched its denosumab biosimilars Conexxence® and Bomyntra® across Europe following European Commission approval in July 2025 for all indications of their reference medicines ...

Mitochondrial DNA has long been treated as a workhorse record of cellular history, but new research suggests it also hides a subtle and previously overlooked form of damage. By uncovering this cryptic ...

Rates of cutaneous manifestations at presentation in the rest ranged from 20% of patients with microscopic polyangiitis to 97 ...

Fossilized bones in Brazil reveal that deadly infections plagued sauropods 80 million years ago. Researchers uncovered unhealed lesions consistent with osteomyelitis, pointing to pathogens spread ...

Patients with giant cell arteritis started tocilizumab therapy an average of 43 days after diagnosis, partly because of delays in insurance approval. Overall, 82 patients (average age, 73 years; 60% ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central nervous system. The findings suggest that neural stem cell-based therapies ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant cell arteritis, according to findings from a team at the Perelman School of ...

In April 2025, the US Food and Drug Administration (FDA) approved Rinvoq ® (upadacitinib; AbbVie, Inc) for the treatment of adults with giant cell arteritis (GCA). Upadacitinib is a Janus kinase (JAK) ...